All In Biotech

Drug Trial Radar · NCT05699759

Safety and Effect of Intravitreal Injection of a Derivative of Nucleoside Reverse Transcriptase Inhibitor in Subjects with Diabetic Macular Edema

A Non-randomized, Open Label, Safety and Efficacy Study Evaluating a Single Dose of Kamuvudine-8 (K8) for the Treatment of Patients with Diabetic Macular Edema

Last checked: Nov 19, 2026Latest source record: Nov 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1

Actual

Start

Jan 4, 2024

Primary completion

Jun 20, 2024

Study completion Jun 20, 2024

Sponsor

Lead sponsor
Michelle Abou-JaoudeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Inflammasome Therapeutics
First posted
Jan 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to assess the safety and initial evidence of efficacy of the novel compound SOM-401 (K8), a derivative of a nucleoside reverse transcriptase inhibitor, in subjects with untreated, clinically significant, diabetic macular edema (DME).

Conditions

  • Diabetic Macular Edema

Interventions

  • K8Drug

    Subjects will have the treatment administered intravitreally (one eye only) using an injector system on a 24-gauge needle to deliver a cylindrical, 3 mm long, drug eluting pellet containing 300 µg of K8. Participants will be followed for 168 days (24 weeks).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change in central subfield thicknessTime frame: At week 4 (change as measured from baseline)
  2. Mean change in best-corrected visual acuity (BCVA)Time frame: At week 4 (change as measured from baseline)
  3. Adverse EventsTime frame: Within the study period (of 24 weeks)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Kentucky

    Lexington, Kentucky

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.